Isosorbide dinitrate
- Generic Name
- Isosorbide dinitrate
- Brand Names
- Bidil, Dilatrate, Isordil
- Drug Type
- Small Molecule
- Chemical Formula
- C6H8N2O8
- CAS Number
- 87-33-2
- Unique Ingredient Identifier
- IA7306519N
- Background
A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action.
- Indication
For the prevention of angina pectoris due to coronary artery disease.
- Associated Conditions
- Angina Pectoris, Heart Failure
- Associated Therapies
- -
Hypertensive Heart Failure Treatment in SSA
- Conditions
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of Abuja
- Target Recruit Count
- 50
- Registration Number
- NCT06400784
- Locations
- 🇳🇬
University of Abuja Teaching Hospital, Abuja, Federal Capital Territory, Nigeria
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Heart Center Research, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06218199
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
Optimized Treatment of Pulmonary Edema or Congestion
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Johannes Grand
- Target Recruit Count
- 1104
- Registration Number
- NCT05276219
- Locations
- 🇩🇰
Nordsjællands Hospital, Hillerød, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen, Denmark
🇩🇰Hvidovre Hospital, Copenhagen, Denmark
Nitrate Effect on Exercise Capacitance
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 20
- Registration Number
- NCT04297241
- Locations
- 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
- Conditions
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 68
- Registration Number
- NCT02789033
Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02718521
- Locations
- 🇨🇳
Chinese People's Liberation Army General Hospital, Peking, Beijing, China
Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF
- Conditions
- Interventions
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Chinese University of Hong Kong
- Registration Number
- NCT02649998
- Locations
- 🇭🇰
Prince of Wales Hospital, Sha Tin, NT, Hong Kong
Medical Management of Late Intrauterine Death.
- Conditions
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- National Institute of Perinatology
- Target Recruit Count
- 60
- Registration Number
- NCT02488642
Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis
- Conditions
- Interventions
- First Posted Date
- 2015-02-23
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT02368795
- Locations
- 🇮🇷
Shariati hospital, Tehran, Iran, Islamic Republic of
Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 100
- Registration Number
- NCT02343393
- Locations
- 🇸🇬
Changi General Hospital, Singapore, Singapore
🇸🇬National Heart Centre Singapore, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.